• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medherant wins grant to support manufacturing program for transdermal drug-delivery patches

October 3, 2018 By Sarah Faulkner

Medherant logo - updatedMedherant said today that it was awarded a Medicines Manufacturing Grant from Innovate UK to support the manufacturing of transdermal drug-delivery patches.

The company plans to expand its pilot-scale GMP manufacturing program, which is designed to make patches formulated with its Tepi patch tech for clinical trials.

Medherant touts its Tepi technology as enabling the development of transdermal patch products with better adhesion and more efficient drug delivery through the skin compared to traditional patches. The company’s first product, an ibuprofen patch, is involved in a Phase I trial with initial results slated for the fourth quarter.

The company develops transdermal patches and then out-licenses them to established pharma companies for commercialization, according to Medherant.

The UK-based company reported that its pilot-scale patch manufacturing plant has successfully produced non-GMP patches of the ibuprofen Tepi patch. Medherant has also reportedly made Tepi patches for other companies that are interested in evaluating Medherant’s technology for their own drugs.

The company noted that it can create candidate patch formulations for third-party groups in just 2-3 months.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: medherant

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS